MX2015009546A - Dosificacion aumentada de efavirenz para el tratamiento de cancer. - Google Patents

Dosificacion aumentada de efavirenz para el tratamiento de cancer.

Info

Publication number
MX2015009546A
MX2015009546A MX2015009546A MX2015009546A MX2015009546A MX 2015009546 A MX2015009546 A MX 2015009546A MX 2015009546 A MX2015009546 A MX 2015009546A MX 2015009546 A MX2015009546 A MX 2015009546A MX 2015009546 A MX2015009546 A MX 2015009546A
Authority
MX
Mexico
Prior art keywords
efavirenz
treatment
cancer
daily dose
relates
Prior art date
Application number
MX2015009546A
Other languages
English (en)
Inventor
Pier Vincenzo Piazza
Nadine Houede
Audrey Laroche-Clary
Original Assignee
Alienor Farma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alienor Farma filed Critical Alienor Farma
Publication of MX2015009546A publication Critical patent/MX2015009546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La invención se basa en el hallazgo que una dosis diaria aumentada de Efavirenz debe utilizarse para el tratamiento de cáncer comparado con la dosis diaria utilizada en el tratamiento de SIDA; la invención de esa forma se refiere al uso de Efavirenz para preparar un medicamento hecho para el tratamiento de cáncer, en donde se administra Efavirenz a una dosis que genera una concentración en plasma de Efavirenz en dicho paciente superior 3000 ng/mI; además se refiere al uso de Efavirenz para preparar un medicamento hecho para el tratamiento de cáncer, en donde se administra Efavirenz a una dosis diaria de al menos 1800 mg, en particular entre 1800 y 2200 mg; también se refiere al uso de Efavirenz para preparar un medicamento hecho para el tratamiento de cáncer, en el cual la dosis diaria de Efavirenz se optimiza después de administración de una dosis diaria preliminar y medida o concentración en plasma de Efavirenz; también se refiera a una forma de dosificación única de Efavirenz, que comprende Efavirenz en una cantidad que genera una concentración en plasma de Efavirenz en dicho paciente superior a 3000 ng/mI, y un portador farmacéuticamente aceptable.
MX2015009546A 2013-01-23 2013-01-23 Dosificacion aumentada de efavirenz para el tratamiento de cancer. MX2015009546A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/000227 WO2014114971A1 (en) 2013-01-23 2013-01-23 Increased dosage of efavirenz for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2015009546A true MX2015009546A (es) 2015-11-25

Family

ID=48014108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009546A MX2015009546A (es) 2013-01-23 2013-01-23 Dosificacion aumentada de efavirenz para el tratamiento de cancer.

Country Status (5)

Country Link
US (1) US9468646B2 (es)
AU (1) AU2013375157B2 (es)
CA (1) CA2898145C (es)
MX (1) MX2015009546A (es)
WO (1) WO2014114971A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214591B1 (en) 2015-04-03 2019-02-26 Alienor Farma Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
CN110418840A (zh) * 2017-01-23 2019-11-05 健康研究股份有限公司 用于预防和治疗癌症与衰老的内源性逆转录酶抑制和细胞靶向
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
CN113384585A (zh) * 2021-04-16 2021-09-14 蓝龙药业(北京)有限公司 依法韦仑在制备治疗小细胞肺癌的药物中的应用
KR20230018341A (ko) * 2021-07-29 2023-02-07 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2023096446A1 (ko) * 2021-11-29 2023-06-01 에스케이케미칼 주식회사 에트라비린의 대사성 질환 및 섬유화 질환 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
DK1469858T3 (da) 2001-12-24 2008-09-29 Ist Superiore Sanita Ikke nucleosidiske inhibitorer for revers transkriptase som antagonister for celleproliferation og induktorer for celledifferentiation
GB2421948A (en) 2004-12-30 2006-07-12 Ist Superiore Sanita Retrotransposon inhibition to treat cancer
WO2008144458A1 (en) * 2007-05-15 2008-11-27 Z & Z Medical Holdings, Inc. Dissolution of arterial cholesterol plaques by pharmacologically induced elevation of endogenous bile salts
WO2011151786A2 (en) * 2010-06-04 2011-12-08 North-West University Injectable formulation

Also Published As

Publication number Publication date
CA2898145C (en) 2021-08-31
AU2013375157A1 (en) 2015-08-06
AU2013375157B2 (en) 2018-07-12
WO2014114971A1 (en) 2014-07-31
US20150366871A1 (en) 2015-12-24
US9468646B2 (en) 2016-10-18
CA2898145A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PH12016500619A1 (en) Dry powder inhaler
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ714963A (en) Compositions and methods for treating anemia
NZ732507A (en) Improved compositions for treating muscular dystrophy
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
PH12019500025A1 (en) Cancer treatment combinations
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2020002310A (es) Formas de dosificacion de alta concentracion de pridopidina.
PH12015502655A1 (en) Method
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2019003339A (es) Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso.
UA115250C2 (uk) Фармацевтичні комбінації
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
NZ760033A (en) Methods to treat opioid use disorder
PH12015500915A1 (en) Bremelanotide therapy for female sexual dysfunction
MX2017009733A (es) Uso de una mezcla de polímeros de glucosa modificados para reducir la metástasis tumoral.
ZA202200330B (en) Pharmaceutical composition of imatinib